Gyre Therapeutics, Inc.
GYRE
$7.08
-$0.57-7.42%
NASDAQ
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Yield Index
Headlines
3/18/2026
-
TipRanks Financial Blog
3/17/2026
-
Globe Newswire
3/15/2026
-
TipRanks Financial Blog
3/14/2026
-
Ticker Report
3/14/2026
-
MarketBeat
3/14/2026
-
Tickeron - Technical Analysis
3/14/2026
-
MarketBeat
3/13/2026
-
TipRanks Financial Blog
3/13/2026
-
Tickeron - Technical Analysis
3/13/2026
-
TipRanks Financial Blog
3/12/2026
-
Simply Wall St
3/12/2026
-
Ticker Report
3/12/2026
-
MarketBeat
3/12/2026
-
Zacks Investment Research
3/12/2026
-
Nasdaq News: Stocks
3/12/2026
-
SeekingAlpha.com: All News
3/12/2026
-
TipRanks Financial Blog
3/12/2026
-
TipRanks Financial Blog
3/12/2026
-
The Fly
3/12/2026
-
Globe Newswire
3/12/2026
-
Tickeron - Stocks
3/11/2026
-
Tickeron - Stocks
3/10/2026
-
Zacks Investment Research
3/10/2026
-
Tickeron - Technical Analysis
3/10/2026
-
Tickeron - Technical Analysis
Income Statement
Total Revenue (TTM)
EBITDA (TTM)
EBIT (TTM)
Net Income (TTM)
Balance Sheet
Total Assets (Q)
Total Debt (Q)
Total Liabilities (Q)
Book Value Per Share (Q)
Cash Flow
Cash from Operations (TTM)
Cash from Investing (TTM)
Cash from Financing (TTM)
Net Change in Cash (TTM)
Filings
Filing Date
Friday, March 13, 2026
Period Date
Wednesday, December 31, 2025
Next Filing
Week of May 4 and 8 (est)
Price History
Beta
7-Day Total Return
30-Day Total Return
60-Day Total Return
90-Day Total Return
Year to Date Total Return
1-Year Total Return
2-Year Total Return
3-Year Total Return
--
5-Year Total Return
--
52-week Low
52-week High
Valuation
Enterprise Value
Price/Sales (TTM)
Price/Book (Q)
Dividends and Shares
Shares Outstanding
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
Phone Number
858-567-7770
Address
12770 High Bluff Drive
San Diego, CA 92130
San Diego, CA 92130
Country
Year Founded
Business Description
Sector
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The...
more